

Article

Solution NMR Structure of the SH3 Domain of Human Caskin1 Validates the Lack of a Typical Peptide Binding Groove and Supports a Role in Lipid Mediator Binding

Orsolya Tőke^{1,*}, Kitti Koprivanacz², László Radnai^{2,†}, Balázs Merő², Tünde Juhász², Károly Liliom³ and László Buday^{2,*}

¹ Laboratory for NMR Spectroscopy, Research Centre for Natural Sciences, 2 Magyar tudósok körútja, H-1117 Budapest, Hungary

² Institute of Enzymology, Research Centre for Natural Sciences, 2 Magyar tudósok körútja, H-1117 Budapest, Hungary; kitti.koprivanacz@gmail.com (K.K.); lradni@gmail.com (L.R.); merobwork@gmail.com (B.M.); juhasz.tunde@ttk.hu (T.J.)

³ Department of Biophysics and Radiation Biology, Semmelweis University, 37-47 Tűzoltó utca, H-1094 Budapest, Hungary; karoly.liliom.mta@gmail.com

* Correspondence: toke.orsolya@ttk.hu (O.T.); buday.laszlo@ttk.hu (L.B.); Tel.: +36-1-382-6575 (O.T.); +36-1-382-6700 (L.B.)

† Current Address: Department of Molecular Medicine and Department of Neuroscience, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA.

Abstract: SH3 domains constitute an important class of protein modules involved in a variety of cellular functions. They participate in protein-protein interactions via their canonical ligand binding interfaces composed of several evolutionarily conserved aromatic residues forming binding grooves for typical (PxxP) and atypical (PxxxPR, RxxK, RKxxY) binding motifs. The calcium/calmodulin-dependent serine protein kinase (CASK)-interacting protein 1, or Caskin1, a multidomain scaffold protein regulating the cortical actin filaments, is enriched in neural synapses in mammals. Based on its known interaction partners and knock-out animal studies, Caskin1 may play various roles in neural function and it is thought to participate in several pathological processes of the brain. Caskin1 has a single, atypical SH3 domain in which key aromatic residues are missing from the canonical binding groove. No protein interacting partner for this SH3 domain has been identified yet. Nevertheless, we have recently demonstrated the specific binding of this SH3 domain to the signaling lipid mediator lysophosphatidic acid (LPA) in vitro. Here we report the solution NMR structure of the human Caskin1 SH3 domain and analyze its structural features in comparison with other SH3 domains exemplifying different strategies in target selectivity. The key differences revealed by our structural study show that the canonical binding groove found in typical SH3 domains accommodating proline-rich motifs is missing in Caskin1 SH3, most likely excluding a bona fide protein target for the domain. The LPA binding site is distinct from the altered protein binding groove. We conclude that the SH3 domain of Caskin1 might mediate the association of Caskin1 with membrane surfaces with locally elevated LPA content.

Keywords: caskin1; SH3 domain; lipid signaling; lysophosphatidic acid; protein-lipid-interaction; NMR spectroscopy; molecular recognition



Citation: Tőke, O.; Koprivanacz, K.; Radnai, L.; Merő, B.; Juhász, T.; Liliom, K.; Buday, L. Solution NMR Structure of the SH3 Domain of Human Caskin1 Validates the Lack of a Typical Peptide Binding Groove and Supports a Role in Lipid Mediator Binding. *Cells* **2021**, *10*, 173. <https://doi.org/10.3390/cells10010173>

Received: 19 November 2020

Accepted: 13 January 2021

Published: 16 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The calcium/calmodulin-dependent serine protein kinase (CASK)-interacting protein 1 or Caskin1, enriched in neuronal synapses in mammals, is an adaptor protein regulating cortical actin filaments [1]. Similar to its isoform, Caskin2, it is a multidomain protein containing six ankyrin repeats, a single Src homology 3 (SH3) domain, two sterile α motif (SAM) domains, an intrinsically disordered proline-rich segment, and a unique C-terminal conserved region [1,2]. In a complex with CASK, Caskin1 associates with the cytoplasmic

tail of neurexin1, a neuron specific adhesion molecule [1]. Regarding the CASK-Caskin1 interaction, a short linear motif in the unstructured linker connecting the SH3 and SAM domains of Caskin1 is known to be responsible for binding to CASK [3]. Similar functional binding motifs were identified in Mint1 and TIAM1, suggesting that Caskin1 may compete with these proteins for CASK binding in vivo [3].

Previously, we demonstrated that Abl interactor-2 (Abi-2) binds to the proline-rich, unstructured region of Caskin1 [2]. Besides CASK and Abi-2, our yeast two hybrid study identified several other proteins as potential interactors of Caskin1, including EphA2 (receptor tyrosine kinase), L1CAM (cell adhesion molecule), Myosin IB (cytoplasmic motor), Nck1 (adaptor), Neurexin 2 (neuronal cell adhesion molecule), Stathmin-like 3 protein (regulator of microtubule stability), Synaptotagmin (mediator of Ca²⁺-regulated vesicle fusion), Septin 4 (cell cycle regulator), and Siah1 (ubiquitin ligase) [2]. Additionally, a homolog of Caskin1 in *Drosophila* was found to be necessary for embryonic motor axon guidance by interacting with the leukocyte common antigen-related (Lar) receptor protein tyrosine phosphatase [4]. An SH2/SH3 adaptor protein, Dock (homolog of human Nck in *Drosophila*), was also identified as a binding partner of Caskin in the same work [4]. While Lar binds to the N-terminal SAM domain of Caskin, Dock has a different binding site, suggesting that they may form a tripartite complex in vivo. [4]. We have also demonstrated the binding of mammalian Nck to Caskin1 [5]. Moreover, we have shown that Nck recruits Caskin1 to EphB1, a receptor tyrosine kinase responsible for cell-cell contact dependent signalization [6]. In the complex, the SH2 domain of Nck binds to the activated receptor, while the SH3 domains of Nck bind the proline-rich C-terminal region of Caskin1 [5]. Intriguingly, a complex formation of the receptor, adaptor, and scaffold proteins results in tyrosine phosphorylation of Caskin1 on its SH3 domain.

Caskin1 has been associated with a number of pathological conditions. A study investigating transcriptomic and proteomic changes in a mouse model strain of autism spectrum disorders (ASDs) identified Caskin1 as a novel gene associated with the ASD-like phenotype [7]. Furthermore, down-regulation of the expression of Caskin1 by a microRNA (miR-21a-5p) has been found to promote the proliferation of porcine hemagglutinating encephalomyelitis virus [8]. Additionally, Caskin1 has been shown to be downregulated in an ischemia/reperfusion injury rat model system both at the mRNA and protein levels, indicating a potential role of Caskin1 in the pathomechanism of stroke [9]. It has also been shown that prenatal exposure to ethanol induces a significant decrease in the expression of Caskin1 in rats, indicating that maternal consumption of alcohol may affect Caskin-related synaptic functions in the brain [10]. Caskin1 may also be involved in the development of anaplastic large-cell lymphoma (ALCL) by being associated with nucleophosmin-anaplastic lymphoma kinase, a chimeric oncogene constitutively overexpressed in ALCL patients [11]. Moreover, it has been shown that the concentration of Caskin1 in the spinal dorsal horn increases during chronic pain and it contributes to various behavioral phenotypes, including nociception, gait, memory, and stress response in broad regions of the central nervous system [12]. More recently, a postsynaptic role of Caskins has been demonstrated in knockout mice with indications that they affect learning abilities by regulating spine morphology and AMPA receptor localization [13]. Additionally, the Caskin1 gene has been found to have deletions in some patients with TSC2/PKD1 contiguous gene deletion syndrome [14,15].

The SH3 domain of Caskins is atypical in a sense that, unlike in conventional SH3 domains [16–18], key conserved aromatic residues necessary for the recognition of canonical (PxxP) and non-canonical Pro-containing motifs in target signaling proteins are missing [19] (Figure 1). Accordingly, no Pro-rich interacting partners have been identified yet. Instead, as we have shown recently, Caskin1 SH3 selectively binds LPA in vitro [20], a signaling-born lysophospholipid mediator activating bona fide G-protein coupled receptors [21,22]. Specifically, as revealed by intrinsic tryptophan measurements, the SH3 domain of Caskin1 selectively binds to oleoyl (18:1) LPA, whereas no binding is observed for oleoyl LPC bearing a phosphocholine headgroup or for the related sphingolipid mediator sphingosine-

1-phosphate [20]. Testing the effect of the saturation level of the hydrocarbon chain on binding further suggested that oleate esterified LPA or oleoyl-cyclic LPA is preferred over saturated palmitoyl LPA. Both fluorescence and ITC measurements have indicated a dependence of the binding interaction on the association state of LPA, with preferred binding of ~nM affinity to micellar LPA, suggesting that the SH3 domain has a preference for LPA-containing lipid surfaces compared to monomeric LPA. Chemical shift perturbation of ¹⁵N-HSQC spectra of Caskin1 SH3 domain indicates no major structural changes upon LPA addition, but reveals a discrete set of amino acids affected by LPA binding [20] (Figure S1). Mapping LPA-induced chemical shift changes to a homology model built based on the solution NMR structure of the SH3 domain of human Caskin2 has suggested that amino acids involved in LPA binding are likely to be distinct from the canonical proline-rich ligand binding groove in the SH3 domain of Src-kinase [20]. The goal of the present study was to obtain an atomic-level structure of human Caskin1 SH3 and analyze its structural features in comparison with SH3 domains known to bind canonical or non-canonical proline-rich peptides. The presented solution NMR structure provides structural evidence for a missing typical peptide binding groove seen in other SH3 domains as well as evidence that the binding surface for LPA is distinct from this altered peptide binding groove, supporting our hypothesis that the SH3 domain of Caskin1 has specialized for the binding of membrane surfaces with locally elevated LPA content during evolution.




Figure 1. Sequence alignment of selected Src homology 3 (SH3) domains. The highly conserved residues that typically interact with the proline-rich ligand in many SH3 domains are shown in bold. Substitutions at some of the key conserved positions are indicated in red. The xP sites and the specificity sites are highlighted in green and pink backgrounds, respectively. Residues having an important role in ligand binding in specific SH3 domains are italicized and shown in aquamarine and magenta depending on whether they interact with the proline-rich segment or the flanking region of the ligand. The secondary structure elements are indicated above the sequence of c-Src. The SH3 sequences shown are as follows. Cski1: human Caskin1, residues 280–347, UniProt accession Q8WXD9; Cski2: human Caskin2, residues 280–347, UniProt accession Q9WXE0, PDB 2KE9; Src: chicken c-Src, residues 80–142, UniProt accession P00523, PDB 1QWE; Fyn: human Fyn tyrosine kinase, residues 81–143, UniProt accession P06241, PDB: 4EIK; Crk: mouse c-Crk, N-terminal SH3 domain, residues 131–192, UniProt accession Q64010, PDB: 1CKA; Abl: mouse tyrosine-protein kinase, residues 60–121, UniProt accession P00520, PDB: 1ABO; Grap2: mouse GRB2-related adhesion protein 2, C-terminal SH3 domain, residues 262–322, UniProt accession O89100, PDB: 1OEB; Lyn: human tyrosine-kinase Lyn, residues 62–163, UniProt accession P07948, PDB: 1W1F; Dnmbp: human dynamin-binding protein C-terminal SH3 domain, residues 1512–1576, UniProt accession Q6XZF7, PDB: 4CC7; Itsn1: human Intersectin-1, residues 912–971, UniProt accession Q15811-1, PDB: 4IIM.

2. Materials and Methods

2.1. Protein Expression and Purification

The coding sequence corresponding to the SH3 domain of human Caskin1 (UniProt: Q8WXD9, residues: 284–346) was obtained from Integrated DNA Technologies as a synthetic gene construct and subsequently subcloned into a modified pET vector harboring a hexahistidine tag and a TEV protease recognition site by using NdeI and BamHI restriction sites. The 6x His-tagged protein was expressed in *E. coli* Rosetta pLysS cells. Cells were grown in 4 × 1000 mL LB medium and supplemented with ampicillin and chlorampheni-

col up to $OD_{600} = 0.6$ at $37\text{ }^{\circ}\text{C}$, while shaking at 250 rpm. Cells were harvested using centrifugation and resuspended in 1 L Minimal Media containing 1 g/L $^{15}\text{N-NH}_4\text{Cl}$ and 5 g/L $^{13}\text{C-D-glucose}$ as single nitrogen and carbon sources, respectively. Protein expression was induced using 0.5 mM isopropyl-thio- β -galactoside (Sigma-Aldrich) at $37\text{ }^{\circ}\text{C}$ for 4 h. Cells were harvested using centrifugation for 20 min at $4\text{ }^{\circ}\text{C}$ and then resuspended in lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 0.5 M EDTA, 1 mM PMSF, $1\times$ complete EDTA-free protease inhibitor cocktail (Roche), pH 8.0). After sonication ($10\times 10\text{ s}$), cell debris was removed using centrifugation ($4\text{ }^{\circ}\text{C}$, 30 min) and the supernatant was purified using a Ni-NTA column (Macherey-Nagel, cat. no. 745400). The target protein was eluted with elution buffer (50 mM HEPES, 30 mM KCl, 5 mM TCEP, pH 7.5) containing 250 mM imidazole. The His-tag was cleaved using TEV protease while dialyzing against the lysis buffer. To remove the protease, residual undigested protein molecules, and digested His-tags, samples were loaded again onto a Ni-NTA column. The flow through was dialyzed against a buffer containing 20 mM K-phosphate, 100 mM KCl, 0.05% NaN_3 , 0.1 mM TCEP, pH = 7.2 (NMR buffer). Purity of the SH3 domain was monitored using SDS-PAGE.

2.2. NMR Spectroscopy

Multidimensional NMR experiments were carried out on a 600 MHz Varian NMR spectrometer equipped with a 5 mm indirect detection triple $^1\text{H}^{13}\text{C}^{15}\text{N}$ resonance z-axis gradient probe in buffer containing 20 mM K-phosphate, 100 mM KCl, 0.05% NaN_3 , 0.1 mM TCEP, pH 7.2 at $10\text{ }^{\circ}\text{C}$. Protein concentration was $\sim 0.6\text{ mM}$. Backbone resonance assignment was obtained on the uniformly [$U\text{-}^{13}\text{C},^{15}\text{N}$]-enriched SH3 domain of human Caskin1 using a combination of two-dimensional (2D) $^1\text{H}\text{-}^{15}\text{N}$ HSQC [23], three-dimensional (3D) gHNCACB [24], gCBACACONH [25], and gHBHA(CO)NH [26] experiments. Side-chain assignments involved 3D CC-TOCSY-NNH [27], 3D HCC-TOCSY-NNH [27], and 3D g-HCCH-TOCSY [28] measurements. Spectral processing, computer assisted spin-system analysis, and resonance assignment was carried out using Felix 2004 (Accelrys, Inc.). The ^1H chemical shifts were referenced externally to 2,2-dimethylsilapentane-5-sulfonic acid (DSS), whereas ^{13}C and ^{15}N chemical shifts were referenced indirectly to DSS [29]. Position and length of secondary structure elements were initially determined from the deviations of $\text{H}\alpha$, $\text{C}\alpha$, and $\text{C}\beta$ chemical shifts from random coil values using CSI [30]. Interproton distance restraints were obtained from aliphatic and aromatic 3D ^{13}C -NOESY-HSQC [31], 3D ^{15}N -NOESY-HSQC [32], 3D Met-Met-NOESY [33], and 2D $^1\text{H}\text{-}^1\text{H}$ NOESY spectra [34]. Structure calculations were performed with ARIA (Ambiguous Restraints for Iterative Assignment, version 2.2) [35] using a log-harmonic shape potential and Bayesian weighting for distance restraints [36]. In each of the seven iterations, the 50 lowest energy structures were used as templates for the next iteration and the 15 best structures were used for restraint violation analysis. The computational algorithm in the structure calculation employed torsional angle simulated annealing followed by torsional angle and Cartesian molecular dynamics cooling stages. Structural refinement was completed in a water shell. The stereochemical quality and structural statistics of the final ensemble were determined using PROCHECK [37], MolProbity [38], and the PDB validation server.

The ^{15}N T_1 , T_2 measurements [39,40] were collected on $U\text{-}[^{15}\text{N}]$ -enriched human Caskin1 at $20\text{ }^{\circ}\text{C}$ at 14.1 T (corresponding to ^1H Larmor frequencies of 600 MHz). The protein concentration was 0.2 mM. Backbone amide ^{15}N T_1 values were measured from two series of eight spectra (24 transients, interscan delay of 1.5 s) with the following relaxation delay times: $T = 20, 100, 190, 290, 390, 530, 670,$ and 830 ms , and $T = 20, 50, 100, 170, 240, 340, 480,$ and 710 ms . Amide ^{15}N T_2 values were obtained similarly: $T = 10, 30, 50, 90, 130, 170, 210,$ and 250 ms , and $T = 10, 30, 70, 90, 110, 150, 190,$ and 230 ms . To map the regions of backbone order and disorder, gradient- and sensitivity-enhanced ^{15}N -HSQC experiments were used to collect amide proton saturation transfer data by recording spectra (32 transients) with and without water presaturation during a 5 s interscan delay [41]. Saturation transfer measurements were carried out in triplicates. Relaxation NMR data were analyzed with CCPNMR.

3. Results

3.1. 3D Solution Structure of the SH3 Domain of Human Caskin1

Sequence specific resonance assignments (Supplementary Table S1) and ^1H - ^1H distance restraints for the human Caskin1 SH3 domain were obtained using standard 3D triple resonance experiments collected on uniformly ^{13}C , ^{15}N -enriched protein at 10 °C, as detailed in Materials and Methods. Elements of the secondary structure were initially identified via the analysis of the deviations of $^1\text{H}_{\alpha}$, $^{13}\text{C}_{\alpha}$, and $^{13}\text{C}_{\beta}$ chemical shifts from random coil values and diagnostic inter-residue ^1H - ^1H nuclear Overhauser effect (NOE) correlations (Figure 2A). As expected, beta-strands are the major elements of the secondary structure. This is evidenced by a consensus chemical shift index as well as stretches of strong sequential $\text{H}_{\alpha,i}$ - HN_{i+1} NOEs complemented with long-range $\text{H}_{\alpha,i}$ - $\text{H}_{\alpha,i+j}$ NOEs between the alpha protons of neighboring β -strands. Additionally, a large number of long-range NOEs were observed between the side chains of residues separated by more than five amino acids corresponding to strand-strand interactions. The distribution of sequential, medium, and long-range NOEs along the amino acid sequence is depicted in Figure 2B. NOE restraints used to determine the tertiary structure of the domain together with statistics for the lowest-energy structural ensemble (Figure 3A) are summarized in Table 1. In ordered protein regions, over 80% of the non-proline, non-glycine residues were in the most favored regions of the Ramachandran plot. The exceptions included residues in more ordered regions of the RT-loop (D291, Y292, S300, N302, K304) and in the n-Src-loop (Q314) assuming (Φ , Ψ) angles in the additionally allowed regions of the Ramachandran plot. A representative element of the lowest-energy structural ensemble is depicted in Figure 3B. Accordingly, the Caskin1 SH3 domain displays a tertiary fold characteristic of SH3 beta-sandwiches. Specifically, a hydrophobic core is defined by two orthogonal antiparallel beta-sheets, with one of the strands (β 2) shared by the two sheets. The hydrophobic core is stabilized by van der Waals interactions between bulky hydrophobic side chains of β 2 (I309, V311, L312) and β 3 (W320, I324), with contribution from β 1 (L284, V286) and the RT-loop (L301). Between β 2 and β 3, as part of the n-Src-loop, residues $^{315}\text{HPDG}^{318}$ form a type I turn stabilized by multiple $i, i + 3$ (between H315 and G318) and $i, i + 4$ (between H315 and R319) backbone H-bonds. Unlike in many other SH3 domains [42], no presence of a 3_{10} helix is observed toward the C-terminus. While residues in the beta-strands show a high degree of convergence (with overall RMSDs from the mean structure of 0.8 and 1.3 Å for backbone and all heavy atoms, respectively), most of the loop regions display a high degree of flexibility (Figure 3C). However, besides the network of backbone H-bonds stabilizing the overall fold, a number of side chain interactions occur between more peripheral elements restricting the motional freedom of these segments. This includes a salt bridge between the side chains of R287 and E343 stabilizing the contact between β 1 and β 5. It is noteworthy that the distal-loop (D326-R333) is involved in multiple H-bond interactions with β 2 (between the side chains of D307 and N327) and the RT-loop (between the side chains of N302 and R333). The distal-loop is further stabilized by favorable electrostatic interactions between the side chains of D326 and K304 (RT-loop). Additionally, an H-bond between the side chains of D326 and N331 occurs in about half of the lowest-energy structural ensemble restricting the conformational space of the loop. Backbone-side chain contacts are also prevalent including the side chains of D307 (β 2), D326 (distal-loop), and R333 (distal-loop). Importantly, the beginning of the RT-loop is restricted by two backbone H-bonds (K290-A305 and Y292-V303) extending the tie between β 1 and β 2.

3.2. Solvent Exchange and Backbone ^{15}N Relaxation

Hydrogen exchange rates characteristic of backbone hydrogen bonding interactions and local unfolding events in proteins [43,44] in general follow the distribution of secondary structure elements in Caskin1 SH3. This is shown in Figure 4A, where the relative intensity (I/I_0) of ^1H - ^{15}N correlations collected with and without solvent presaturation is depicted along the amino acid sequence. The two longest continuous segments exhibiting rapid

hydrogen exchange are C293-S300 of the RT-loop and H325-G330 of the distal-loop. The most protected surface from solvent exchange is comprised of $\beta 2$ and the middle segments of $\beta 1$ and $\beta 3$. $\beta 4$ is considerably more susceptible to solvent exchange, whereas via two strong H-bonds to Q285 of $\beta 1$, the C-terminal half of $\beta 5$ gains an increased protection.

In some SH3 domains, such as in Fyn tyrosine kinase, NMR measurements have indicated the presence of a low-populating folding intermediate in equilibrium with its unfolded and fully folded states at ambient temperatures [45]. As low populated higher energy states including partially unfolded states could play a role in molecular recognition processes mediated by the SH3 domain of Caskin1 as well, we examined the possibility of the contribution of conformational exchange to transverse relaxation. The ratio of longitudinal (T_1) and transverse (T_2) ^{15}N relaxation times, a diagnostic marker of conformational exchange processes on the μs -ms timescale, is plotted in Figure 4B as a function of the amino acid sequence. Values of T_1/T_2 exceeding the average by more than one standard deviation have been found sporadically throughout the protein at residues L298 (RT), V303 (RT), I308 ($\beta 2$), Q314 (n-Src), G322 ($\beta 3$), and Y328 ($\beta 4$). Among them, L298, Q314, and Y328 exhibit intensive solvent exchange as well. The absence of continuous segments of elevated T_1/T_2 values shows that slow conformational fluctuations do not provide a significant contribution to transverse relaxation and the Caskin1 SH3 domain is fairly rigid on the μs -ms timescale.




Figure 2. Summary of NMR structural parameters. **(A)** NOEs observed between residue pairs i and $i + j$ are indicated in black. In the last row, NOEs between the alpha protons of residues separated by more than eight amino acids are diagnostic markers of strand-strand interactions in beta-sheets. The amino acid sequence of Caskin1 SH3 is shown at the top using the numbering of the complete human Caskin1 sequence. Residues with a consensus chemical shift index (CSI) indicating a beta-strand conformation as obtained from the analysis of the deviation of H_{α} , C_{α} , and C_{β} chemical shifts from random coil values are highlighted in blue. No 3_{10} helix is observed toward the C-terminus. **(B)** Distribution of NOE restraints. Intra-residue NOEs are in grey, sequential NOEs are in blue, NOEs between residues i and $i + j$, where $2 < j < 5$ are in green, and long-range NOEs are in magenta.




Figure 3. Results of NMR structure calculation. **(A)** Superposition of the 30 lowest-energy conformations obtained for the backbone atoms of the SH3 domain of human Caskin1. **(B)** Ribbon diagram of the most representative member of the lowest-energy structural ensemble. Secondary structure elements are labeled. Beta-strand $\beta 2$ is shared by the front ($\beta 5$, $\beta 1$, $\beta 2$) and back ($\beta 2$, $\beta 3$, $\beta 4$) beta-sheets. **(C)** Average backbone RMSDs from the mean of the 30 lowest-energy conformations of the SH3 domain of human Caskin1. Secondary structure elements along the amino acid sequence are indicated at the top.

Table 1. Statistics and stereochemical quality of the lowest-energy NMR structural ensemble (30 structures) of the human Caskin1 SH3 domain in aqueous buffer (20 mM K-phosphate, 100 mM KCl, 0.05% NaN_3 , 0.1 mM TCEP, pH 7.2) at 10 °C. The analysis was carried out using Procheck and the Protein Structure Validation Suite (PSVS). Glycines, prolines, and residues in disordered regions were excluded from the Ramachandran analysis.

Distance restraints from NOEs	
unambiguous	809
intraresidue	307
sequential	152
$i-i + j$, where $j = 2, 3$, or 4	74
$i-i + j$, where $j > 4$	276
ambiguous	180
Ensemble RMSD values	
All backbone atoms	1.3 Å

Table 1. *Cont.*

All heavy atoms	1.8 Å
All backbone atoms in ordered regions	0.8 Å
All heavy atoms in ordered regions	1.3 Å
Statistics	
Ramachandran plot statistics (ordered protein regions)	
Residues in most favored regions [A, B, L], %	81.5
Residues in additionally allowed regions [a, b, l, p], %	18.3
Residues in generously allowed regions [~a, ~b, ~l, ~p], %	0.2
Residues in disallowed regions, %	0.0
Main-chain statistics	
SD of ω angle, degrees	3.9
Bad contacts/100 residues	0
C $_{\alpha}$ chirality, SD of ζ angle, degrees	1.2
SD of H-bond energy, kcal/mol	0.9
Overall G-factor	−0.1
Side-chain statistics	
χ -1 gauche minus SD, degrees	7.3
χ -1 trans SD, degrees	9.1
χ -1 gauche plus SD, degrees	9.7
χ -1 pooled SD, degrees	10.7
χ -2 trans SD, degrees	12.0

3.3. Mapping LPA-Induced Chemical Shift Perturbations on the NMR Structure of Human Caskin1 SH3 Domain

As we have shown previously, addition of oleoyl LPA to the human Caskin1 SH3 domain (lipid-to-protein molar ratio of 10) induces above-average chemical shift perturbations (Figure S1) in a discrete set of amino acids involving residues of β 1– β 5 (V286, I309–T310, C323, H325, R328, R333–V334, A344), the $^{313}\text{EQH}^{315}$ triad of the n-Src-loop together with W320 at the beginning of β 3, and sporadically at other positions, primarily with side chains capable of H-bond formation (Y296, N302, S339). Notably, the binding of LPA induces a peak doubling for a small number of residues including V346 and I308 as well as the side chain NH₂ groups of N302 and N327. The affected amino acid positions are mapped onto the solution NMR structure of the human Caskin1 SH3 domain in Figure 5A. The majority of the perturbations in the hydrophobic core of the domain suggest that besides the favorable electrostatic interaction of arginines (and depending on their charged state, perhaps the histidines as well) with the LPA headgroups, the hydrophobic acyl chains of LPA may insert deeply into the protein interior. The involvement of residues with H-bond donor/acceptor side chains also suggests the rearrangement of bound water molecules upon LPA binding. Importantly, the most significant changes in the chemical environment upon the interaction with LPA are detected in regions distinct from the canonical PxxP or non-canonical proline-rich peptide binding site of SH3 domains in general (cf below). Based on the Gonnet Pam250 matrix [46], using the groupings of ‘STA’, ‘NEQK’, ‘NHQK’, ‘NDEQ’, ‘QHRK’, ‘MILV’, ‘MILF’, ‘HY’, ‘FYW’, and ‘C’ for the analysis of sequence similarity, the majority of LPA-affected residues are well conserved among Caskins (Figure 5B), whereas they are not conserved among SH3 domains in general, indicating that LPA recognition is likely to be specific to Caskins.




Figure 4. Summary of NMR parameters diagnostic of slow motions and local unfolding events in the SH3 domain of human Caskin1. **(A)** Ratio of relative peak intensities with (I) and without (I_0) presaturation of the solvent resonance and **(B)** ratio of the longitudinal (T_1) and transverse (T_2) relaxation times as a function of the amino acid sequence. Error bars are shown. Dashed lines correspond to the mean and the mean plus one standard deviation. At residues marked with an asterisk in **(A)** fast solvent exchange obscures the analysis. Secondary structural elements are indicated at the top. Longitudinal and transverse relaxation times averaged around $T_1 = 449 \pm 42$ ms and $T_2 = 149 \pm 23$ ms, respectively, matching the values expected for an ~70-residue globular protein at the investigated temperature (20 °C).




Figure 5. Interaction of human Caskin1 SH3 with oleoyl LPA. **(A)** Representative element of the lowest-energy structural ensemble of the SH3 domain of human Caskin1 highlighting the residues with above average oleoyl LPA-induced (lipid-to-protein molar ratio of 10:1) backbone (^1H , ^{15}N) chemical shift change (Figure S1). The region corresponding to the peptide binding groove in the SH3 domain of Src kinase are shown in black. **(B)** Sequence alignment of selected Caskin1 and Caskin2 SH3 domains. Residues with chemical shift change exceeding the average upon the addition of LPA are highlighted in blue revealing a high degree of conversion in Caskins. The sequence of the SH3 domain of c-Src is shown at the top for comparison together with the secondary structure elements. Non-conserved amino acid replacements affected by LPA binding is indicated in red. Amino acid positions corresponding to the peptide binding groove in c-Src are marked by an asterisk. The SH3 sequences shown as follows. Src: c-Src, *Gallus gallus* (UniProt P00523); Caskin1, *Homo sapiens* (UniProt Q8WXD9); Caskin2, *Homo sapiens* (UniProt Q9WXE0); Caskin1, *Rattus norvegicus* (UniProt Q8VHK2); Caskin2, *Xenopus laevis* (UniProt Q6DD51); Caskin1, *Mus musculus* (UniProt Q6P9K8); Caskin2, *Salmo salar* (UniProt A0A1S3QUC9); Caskin2, *Vulpes vulpes* (UniProt A0A3Q7T5U3); Caskin1, *Lipotes vexillifer* (UniProt A0A340X375); Caskin2, *Ursus arctos horribilis* (UniProt A0A3Q7TV80); Caskin1, *Sus scrofa* (UniProt I3LCF2).

3.4. Comparison with the SH3 Domain of Human Caskin2

Comparison of the Caskin1 SH3 domain and its isoform, human Caskin2 (PDB: 2ke9 [18]) reveals differences primarily in the loop regions as well as in the linker connecting the β_4 and β_5 beta-strands. This is shown in Figure 6A, where the lowest-energy element of the structural ensemble of Caskin1 and Caskin2 is superimposed, and in Figure 6B, where C_α positional differences (d_{C_α}) between the mean structures of the two ensembles are depicted along the amino acid sequence. The region exhibiting the largest difference between the two isoforms is the distal- and the n-Src-loop with values of d_{C_α} exceeding 6 Å. Among the two, the distal-loop shows a significantly larger conformational heterogeneity

in Caskin2 with C_{α} RMSDs of the structural ensemble approaching 10 Å in the central segment of the loop (Figure 6C). In Caskin1, the H325-N331 region appears to be more defined due to favorable electrostatic interactions between the side chains of D326 and K304 of the RT-loop (Figure 6D). The NH_3^+ group of the lysine is further stabilized by the proximate D307. In Caskin2, the lysine is replaced by an arginine, and instead of the distal-loop, it forms contacts with D291 located in the N-terminal end of the RT-loop. Another important difference between the two isoforms is the n-Src-loop, which in Caskin1 assumes a type I turn stabilized by two H-bonds (Figure 6E). In Caskin2, W320 ($\beta 3$), following immediately the n-Src-loop, forms hydrophobic contacts with F337 of $\beta 4$ and P339 of the 3_{10} helix, pulling $\beta 3$ slightly away from $\beta 2$, yielding a looser n-Src-loop and hindering the formation of a well-defined turn. While in Caskin2 the 3_{10} helix ($^{339}PGI^{341}$) is stabilized by two hydrogen-bonds, in Caskin1 the corresponding $^{338}PSSL^{341}$ segment appears to be more flexible. The lack of the formation of a stable 3_{10} helix in Caskin1 is suggested by the analysis of chemical shifts, the observed strong solvent exchange at S340 (Figure 4A), and the low number of NOEs in the region. We note that despite the high degree of overall sequence similarity between the SH3 domains of Caskin1 and Caskin2, this region, i.e., the linker between $\beta 4$ and $\beta 5$ together with $\beta 5$, shows significant dissimilarities (Figure 1). It is noteworthy that the arrangement of the residues in the altered peptide binding groove in the SH3 domain of Caskin1 and Caskin2 are highly similar. Among the regions found to be affected by LPA in Caskin1 SH3, the n-Src-loop differs the most.

3.5. Comparison with other SH3 Domains

As we noted in the introduction, the SH3 domains of human Caskin1 and Caskin2 are unique in the sense that some of the aromatic residues having a major role in the binding of Pro-rich sequences in other SH3 domains are substituted by amino acids with positively charged or small hydrophobic side chains. This is demonstrated in Figure 7A, where human Caskin1 is superimposed on the complex of Src SH3 with APP12 ($^1APPLPPRNRPRL^{12}$), a canonical high-affinity Pro-rich peptide selected from a phage display library [47]. The two dipeptide units of APP12 (Ala_1-Pro_2 and Leu_4-Pro_5) bind to the hydrophobic clefts formed by Y90 (in Figure 7A, Y^1), Y136 (Y^2) (pocket 1) and Y92 (Y^3), W118 (W^4), and Y136 (Y^2) (pocket 2) of Src-SH3, respectively. Among the flanking residues, Arg_7 packs against the side chain of W118 and forms a salt bridge with D99 (D^5) near the RT-loop (pocket 3). As shown in Figure 7A, in Caskin1, three of the key aromatic residues are substituted with K290 (K^1), R319 (R^4), and L341 (L^2), whereas the aspartate of the specificity pocket is replaced by a serine.

Besides the xP binding site, even larger differences exist between the specificity site of the SH3 domain of Caskin1 and that of c-Crk (Figure 7B). As revealed by the X-ray structure of the N-terminal Crk-SH3 domain in a complex with a high affinity peptide ($^1PPPALPPKKR^{10}$) from the guanine nucleotide exchange factor (C3G) [48], a lysine residue is tightly coordinated by three acidic residues of the RT-loop. Binding of the flanking region is stabilized by three simultaneous hydrogen-bonds between the carboxylates and the sp^3 hybridized amino group of the lysine. As noted by the authors, the high specificity of the interaction is highlighted by the observed disorder in the complex with a mutant peptide, where Lys_8 is replaced by an arginine. While the lysine-carboxylate interaction is unique to c-Crk SH3 and its relatives, it is a remarkable example of a specifically evolved mode of recognition to overcome the limited variability of binding motifs on the proline-rich ligand. When comparing it to Caskin1 SH3, in addition to the missing hydrophobic interaction at the canonical binding site (Figure 7B, left), there is significantly less acidic residues in the RT-loop and the ones present are positioned in a non-optimal geometry for the binding of positively charged (either Arg or Lys) flanking residues in Pro-rich peptides (Figure 7B, right).




Figure 6. Structural comparison of the SH3 domains of human Caskin1 and Caskin2. (A) Superimposed ribbon diagrams of the lowest-energy element of the structural ensemble of the SH3 domains of human Caskin1 (yellow, PDB: 7ATY) and Caskin2 (grey, PDB: 2KE9 [18]). (B) C_α positional differences between the mean structures of the Caskin1 and Caskin2 SH3 structural ensemble. (C) Average C_α RMSDs based on pairwise distances between matched atoms in the lowest-energy structural ensemble of the SH3 domain of human Caskin1 (grey) and Caskin2 (white). Dashed lines in (B) and (C) at 2 Å are for better viewing. (D,E) Superimposed diagrams of the Caskin1 (yellow) and Caskin2 (grey) SH3 domains highlighting (D) stabilizing electrostatic interactions between the RT- (K304) and the distal-loops (D326) and (E) the formation of a type I turn in the n-Src-loop of Caskin1. Stabilizing H-bonds between the backbone atoms of H315, G318, and R319 are indicated by dashed lines. Hydrophobic interactions of W320 with F337 and P339 of the 3₁₀-helical region in Caskin2 SH3 are shown in grey. Nitrogen and oxygen atoms are shown in blue and red, respectively. See text for details.




Figure 7. Superimposed ribbon diagrams of the SH3 domains of human Casin1 (yellow, PDB: 7ATY) and (A) c-Src complexed with a proline-rich ligand (grey, PDB: 1QWE [47]), (B) c-Crk complexed with a proline-rich ligand (grey, PDB: 1CKA [48]), (C) intersectin-1 complexed with a synthetic proline-rich peptide (grey, PDB: 4IIM [49]). Side chains that have been found crucial for ligand binding in typical SH3 domains are indicated as sticks. For clarity, in the case of c-Crk, the PxxP (left) and specificity (right) site are shown separately. Aromatic (green) and acidic (cyan) residues, which have a key role in binding and are replaced by other residues (black) in Casin1 are highlighted. Residue numbers are omitted for clarity. Superscripts are used to mark the same amino acid position in the superimposed structures to highlight the replacements in Casin1. Oxygen, nitrogen, and sulfur atoms are in red, blue, and yellow, respectively. Ligands are shown in magenta.

The adaptability and the divergent strategies of recognition by SH3 domains are further exemplified by a complex of one of the SH3 domains of human intersectin-1 (Its1) with a non-canonical peptide ligand [49]. A synthetic peptide ${}^1\text{WRDSSGYVMGPW}^{12}$ with a K_d of $\sim 50 \mu\text{M}$ has been shown to interact with a specificity site and a novel exosite on the surface of the Its1 SH3 domain, different from the canonical PxxP binding site. However, even the interaction with the specificity site possesses features differing from common motifs observed in SH3 domains. Specifically, instead of positively charged flanking residues, the C-terminal GPW triad of the ligand packs against a hydrophobic pocket encompassed by M948 (M^4), W949 (W^5), and W959 (W^7) (Figure 7C). The longer WRDSSGYVM region of the peptide binds to an exosite, where hydrophobic interactions together with hydrogen-bonds and a salt bridge stabilize the complex.

4. Discussion

SH3 domains are one of the most prevalent protein modules in nature involved in a variety of cellular functions including cell growth and differentiation, cytoskeletal rearrangements and cell motility, signal transduction, protein degradation, and immune response [19,50]. Primarily, they are known to recognize Pro-rich motifs, in particular the canonical PxxP motifs in proteins [16,51], forming a left-handed, polyproline type II helix in either of two well-defined orientations (class I and II) [47,52]. However, in recent years, there is growing evidence of alternative binding motifs underlying the broader range of specificity of SH3 domains. These atypical binding motifs include both proline-containing motifs (e.g., PxxxPR [53], PxxDY [54]) and those spared of proline, e.g., RxxK [55–57] and RKxxY [58,59]. In the latter, the phosphorylation state of the tyrosine has been shown to regulate the binding interaction suggesting that peptide recognition by SH3 may be coupled to phosphotyrosine signaling. This is supported by subsequent studies showing also that phosphorylation of tyrosines in SH3 domains themselves can lead to the inhibition of partner binding. Specifically, in a recent study of Abl1 and Abl2 SH3 domains, we have shown that two specific simultaneously-phosphorylated tyrosines hinder ligand binding by sterically blocking the ligand binding groove with the phosphate groups [60].

In both canonical and non-canonical peptide recognition, besides the set of conserved, primarily aromatic residues comprising the binding groove, an additional key element of interaction is the specificity site contributed mainly by the RT- and n-Src-loops. In most cases, it involves a pocket of negatively charged residues recognizing a basic Arg or Lys on the binding partner flanking the central motif (Figure 7A,B). Additionally, a conserved tryptophan following the n-Src-loop (Figure 1) often forms stabilizing van der Waals and cation- π interactions with the binding partner. Importantly, the length and sequence of the RT- and n-Src-loops display a variety among SH3 domains resulting in structurally diverse specificity sites, which may recognize peptide motifs other than the canonical with a positively charged flanking residue (Figure 7C) [49]. Additionally, besides the utilization of specific recognition elements, SH3 domains have also been shown to associate with other proteins via tertiary contacts without the involvement of a specific binding motif. Examples include the interaction between the Sla1 SH3 domain and ubiquitin [61] as well as the Fyn SH3 domain and the SAP SH2 domain [62]. Taken together, despite the common architecture of the SH3 domain, via a combinatorial use of the xP binding site and the specificity site, diverse strategies for partner recognition are observed across the family [17].

The SH3 domain of human Caskin1 differs from typical SH3 domains as some of the key aromatic residues involved in ligand binding are substituted by basic or small hydrophobic residues (Figures 1 and 7A,B). Additionally, some of the negatively charged residues in the RT-loop are also missing. Instead, the distal-loop possesses an acidic patch involving D326 and D332 (unlike for instance the SH3 domain of Src kinase). Additionally, a repositioning of acidic residues is found in the n-Src-loop. Mapping of the residues involved in LPA binding to the NMR structure of human Caskin1 SH3 presented for the first time in the current study provides structural evidence for the missing proline-rich peptide binding groove and undoubtedly shows that LPA binding involves a protein region distinct from the peptide binding groove present in SH3 domains in general. The SH3 domain of human Caskin1 is not the only SH3 domain reported to date with a capability of lipid binding. Helical extended specialized SH3 domains have been reported to bind acidic phospholipids [63,64]. More recently, lipid binding by c-Src SH3 has been shown involving residues of the RT- and n-Src-loops forming a binding site opposite to the classical peptide binding site but overlapping with the region interacting with the Unique domain of c-Src. This suggests a complex interplay with membranes and an additional layer of regulation in c-Src signal transduction [65].

In conclusion, while adaptability is essential for the evolution of novel pathways and the modulation of signaling events, discrimination between potential binding partners is of high importance. We hypothesize that selective binding to LPA allows the anchoring of Caskin1 SH3 to membrane microdomains where LPA accumulates due to elevated

production in specific signaling events. Thus, by serving as docking sites for the SH3 domain, lysophosphatidate residing within the plasma membrane may contribute to the guiding of Caskin1 interaction networks. For instance, based on the competing binding of Mint1- and Caskin1-CASK complexes to the cytoplasmic tail of neurexin, one can hypothesize that a coincident LPA signaling event might modulate the signaling of this protein network. Taken together, our structural data support a novel mode of recognition in Caskin1 signal transduction, where affinity and specificity can be tuned by imposing a spatial and temporal regulation of its interaction domain by LPA.

Supplementary Materials: The following are available online at <https://www.mdpi.com/2073-4409/10/1/173/s1>, Figure S1: Oleoyl LPA-induced NMR spectral changes. Table S1: Assigned chemical shifts of the SH3 domain of human Caskin1.

Author Contributions: Conceptualization, K.L., L.B., O.T., L.R.; NMR spectroscopic measurements and data analysis, O.T., K.K., L.R.; protein expression and purification, K.K., B.M., T.J.; manuscript writing, O.T., L.R., K.L.; supervision K.L., L.B.; project administration and funding acquisition K.L., L.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by grants from the National Research, Development, and Innovation Fund of Hungary (K124045, K82092, K109035, FIEK_16-1-2016-0005 and HunProEx 2018-1.2.1-NKP-2018-00005), the MedinProt Program of the Hungarian Academy of Sciences to LB and KL, the “MTA Postdoctoral Fellowship Program” of the Hungarian Academy of Sciences to LR, and by the Ministry for National Economy VKSZ_12-1-2013-001 to LB and KL.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are openly available in the RCSB PDB database (accession number 7ATY) and in the Biological Magnetic Resonance Bank (accession number BMRB 50543).

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Tabuchi, K.; Biederer, T.; Butz, S.; Sudhof, T.C. CASK participates in alternative tripartite complexes in which Mint 1 competes for binding with caskin 1, a novel CASK-binding protein. *J. Neurosci.* **2002**, *22*, 4264–4273. [[CrossRef](#)] [[PubMed](#)]
2. Balazs, A.; Csizmok, V.; Buday, L.; Rakacs, M.; Kiss, R.; Bokor, M.; Udupa, R.; Tompa, K.; Tompa, P. High levels of structural disorder in scaffold proteins as exemplified by a novel neuronal protein, CASK-interactive protein1. *FEBS J.* **2009**, *276*, 3744–3756. [[CrossRef](#)] [[PubMed](#)]
3. Stafford, R.L.; Ear, J.; Knight, M.J.; Bowie, J.U. The molecular basis of the Caskin1 and Mint1 interaction with CASK. *J. Mol. Biol.* **2011**, *412*, 3–13. [[CrossRef](#)] [[PubMed](#)]
4. Weng, Y.L.; Liu, N.; DiAntonio, A.; Broihier, H.T. The cytoplasmic adaptor protein Caskin mediates Lar signal transduction during *Drosophila* motor axon guidance. *J. Neurosci.* **2011**, *31*, 4421–4433. [[CrossRef](#)]
5. Pesti, S.; Balazs, A.; Udupa, R.; Szabo, B.; Fekete, A.; Bogel, G.; Buday, L. Complex formation of EphB1/Nck/Caskin1 leads to tyrosine phosphorylation and structural changes of the Caskin1 SH3 domain. *Cell Commun. Signal.* **2012**, *10*, 36. [[CrossRef](#)]
6. Stein, E.; Lane, A.A.; Cerretti, D.P.; Schoeckmann, H.O.; Schroff, A.D.; Van Etten, R.L.; Daniel, T.O. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. *Genes Dev.* **1998**, *12*, 667–678. [[CrossRef](#)]
7. Daimon, C.M.; Jasien, J.M.; Wood, W.H., 3rd; Zhang, Y.; Becker, K.G.; Silverman, J.L.; Crawley, J.N.; Martin, B.; Maudsley, S. Hippocampal Transcriptomic and Proteomic Alterations in the BTBR Mouse Model of Autism Spectrum Disorder. *Front. Physiol.* **2015**, *6*, 324. [[CrossRef](#)]
8. Lv, X.; Zhao, K.; Lan, Y.; Li, Z.; Ding, N.; Su, J.; Lu, H.; Song, D.; Gao, F.; He, W. miR-21a-5p Contributes to Porcine Hemagglutinating Encephalomyelitis Virus Proliferation via Targeting CASK-Interactive Protein1 In vivo and vitro. *Front. Microbiol.* **2017**, *8*, 304. [[CrossRef](#)]
9. Datta, A.; Jingru, Q.; Khor, T.H.; Teo, M.T.; Heese, K.; Sze, S.K. Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers. *J. Proteome Res.* **2011**, *10*, 5199–5213. [[CrossRef](#)]

10. Middleton, F.A.; Carrierfenster, K.; Mooney, S.M.; Youngentob, S.L. Gestational ethanol exposure alters the behavioral response to ethanol odor and the expression of neurotransmission genes in the olfactory bulb of adolescent rats. *Brain Res.* **2009**, *1252*, 105–116. [[CrossRef](#)]
11. Crockett, D.K.; Lin, Z.; Elenitoba-Johnson, K.S.; Lim, M.S. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. *Oncogene* **2004**, *23*, 2617–2629. [[CrossRef](#)] [[PubMed](#)]
12. Katano, T.; Takao, K.; Abe, M.; Yamazaki, M.; Watanabe, M.; Miyakawa, T.; Sakimura, K.; Ito, S. Distribution of Caskin1 protein and phenotypic characterization of its knockout mice using a comprehensive behavioral test battery. *Mol. Brain* **2018**, *11*, 63. [[CrossRef](#)] [[PubMed](#)]
13. Bencsik, N.; Pusztai, S.; Borbély, S.; Fekete, A.; Dülk, M.; Kis, V.; Pesti, S.; Vas, V.; Szűcs, A.; Buday, L.; et al. Dendritic spine morphology and memory formation depend on postsynaptic Caskin proteins. *Sci. Rep.* **2019**, *9*, 16843. [[CrossRef](#)] [[PubMed](#)]
14. Oyazato, Y.; Iijima, K.; Emi, M.; Sekine, T.; Kamei, K.; Takanashi, J.; Nakao, H.; Namai, Y.; Nozu, K.; Matsuo, M. Molecular analysis of TSC2/PKD1 contiguous gene deletion syndrome. *Kobe J. Med. Sci.* **2011**, *57*, E1–E10.
15. Boehm, D.; Bacher, J.; Neumann, H.P. Gross genomic rearrangement involving the TSC2-PKD1 contiguous deletion syndrome: Characterization of the deletion event by quantitative polymerase chain reaction deletion assay. *Am. J. Kidney Dis.* **2007**, *49*, e11–e21. [[CrossRef](#)] [[PubMed](#)]
16. Ren, R.; Mayer, B.J.; Cicchetti, P.; Baltimore, D. Identification of a ten amino acid proline-rich SH3 binding site. *Science* **1993**, *259*, 1157–1161. [[CrossRef](#)]
17. Saksela, K.; Permi, P. SH3 domain ligand binding: What's the consensus and where's the specificity? *FEBS Lett.* **2012**, *586*, 2609–2614. [[CrossRef](#)]
18. Kwan, J.J.; Donaldson, L.W. A lack of peptide binding and decreased thermostability suggests that the CASKIN2 scaffolding protein SH3 domain may be vestigial. *BMC Str. Biol.* **2016**, *16*, 14. [[CrossRef](#)]
19. Mayer, B.J. SH3 domains: Complexity in moderation. *J. Cell. Sci.* **2001**, *114*, 1253–1263.
20. Koprivanacz, K.; Toke, O.; Besztercei, B.; Juhasz, T.; Radnai, L.; Mero, B.; Mihaly, J.; Peter, M.; Balogh, G.; Vigh, L.; et al. The SH3 domain of Caskin1 binds to lysophosphatidic acid suggesting a direct role for the lipid in intracellular signaling. *Cell. Signal.* **2017**, *32*, 66–75. [[CrossRef](#)]
21. Moolenaar, W.H.; van Meeteren, L.A.; Giepmans, B.N. The ins and outs of lysophosphatidic acid signaling. *Bioessays* **2004**, *26*, 870–881. [[CrossRef](#)] [[PubMed](#)]
22. Xiang, H.; Lu, Y.; Shao, M.; Wu, T. Lysophosphatidic Acid Receptors: Biochemical and Clinical Implications in Different Diseases. *J. Cancer* **2020**, *11*, 3519–3535. [[CrossRef](#)] [[PubMed](#)]
23. Kay, L.E.; Keifer, P.; Saarinen, T. Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. *J. Am. Chem. Soc.* **1992**, *114*, 10663–10665. [[CrossRef](#)]
24. Wittekind, M.; Mueller, L. HNCACB, a high-sensitivity 3D NMR experiment to correlate amide-proton and nitrogen resonances with the alpha- and beta-carbon resonances in proteins. *J. Magn. Reson. Ser. B* **1993**, *101*, 201–205. [[CrossRef](#)]
25. Grzesiek, S.; Bax, A. Correlating backbone amide and side chain resonances in larger proteins by multiple relayed triple resonance NMR. *J. Am. Chem. Soc.* **1992**, *114*, 6291–6293. [[CrossRef](#)]
26. Grzesiek, S.; Bax, A. Amino acid type determination in the sequential assignment procedure of uniformly ¹³C/¹⁵N-enriched proteins. *J. Biomol. NMR* **1993**, *3*, 185–204. [[CrossRef](#)]
27. Grzesiek, S.; Anglister, J.; Bax, A. Correlation of backbone amide and aliphatic side-chain resonances in ¹³C/¹⁵N-enriched proteins by isotropic mixing of ¹³C magnetization. *J. Magn. Res.* **1993**, *101*, 114–119. [[CrossRef](#)]
28. Kay, L.E.; Xu, G.Y.; Singer, A.U.; Muhandiram, D.R.; Forman-Kay, J.D. A gradient enhanced HCCH-TOCSY experiment for recording side-chain proton and carbon-13 correlations in water samples of proteins. *J. Magn. Res. B* **1993**, *101*, 333–337. [[CrossRef](#)]
29. Markley, J.L.; Bax, A.; Arata, Y.; Hilbers, C.W.; Kaptein, R.; Sykes, B.D.; Wright, P.E.; Wüthrich, K. Recommendations for the presentation of NMR structures of proteins and nucleic acids. *J. Mol. Biol.* **1998**, *280*, 933–952. [[CrossRef](#)]
30. Wishart, D.S.; Sykes, B.D. The ¹³C chemical-shift index: A simple method for the identification of protein secondary structure using ¹³C chemical-shift data. *J. Biomol. NMR* **1994**, *4*, 171–180. [[CrossRef](#)]
31. Muhandiram, D.R.; Farrow, N.A.; Xu, G.Y.; Smallcombe, S.H.; Kay, L.E. A gradient ¹³C NOESY-HSQC experiment for recording NOESY spectra of ¹³C-labeled protein dissolved in H₂O. *J. Magn. Reson. B* **1993**, *102*, 317–321. [[CrossRef](#)]
32. Marion, D.; Kay, L.E.; Sparks, S.W.; Torchia, D.A.; Bax, A. Three-dimensional heteronuclear NMR of nitrogen-15 labeled proteins. *J. Am. Chem. Soc.* **1989**, *111*, 1515–1517. [[CrossRef](#)]
33. Zwanen, C.; Gardner, K.H.; Sarma, S.P.; Horita, D.A.; Byrd, R.A.; Kay, L.E. An NMR experiment for measuring methyl–methyl NOEs in ¹³C-labeled proteins with high resolution. *J. Am. Chem. Soc.* **1998**, *120*, 7617–7625. [[CrossRef](#)]
34. Kumar, A.; Ernst, R.R.; Wüthrich, K. A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules. *Biochem. Biophys. Res. Commun.* **1980**, *95*, 1–6. [[CrossRef](#)]
35. Rieping, W.; Habeck, M.; Bardiaux, B.; Bernard, A.; Malliavin, T.E.; Nilges, M. ARIA2: Automated NOE assignment and data integration in NMR structure calculation. *Bioinformatics* **2007**, *23*, 381–382. [[CrossRef](#)]
36. Mareuil, F.; Malliavin, T.E.; Nilges, M.; Bardiaux, B. Improved reliability, accuracy and quality in automated structure calculation with ARIA. *J. Biomol. NMR* **2015**, *62*, 425–438. [[CrossRef](#)]

37. Laskowski, R.A.; MacArthur, M.W.; Moss, D.S.; Thornton, J.M. PROCHECK: A program to check the stereochemical quality of protein structures. *J. Appl. Crystallogr.* **1993**, *26*, 283–291. [[CrossRef](#)]
38. Davis, I.W.; Leaver-Fay, A.; Chen, V.B.; Block, J.N.; Kapral, G.J.; Wang, X.; Murray, L.W.; Arendall, W.B., 3rd; Snoeyink, J.; Richardson, J.S.; et al. MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res.* **2007**, *35*, W375–W383. [[CrossRef](#)]
39. Kay, L.; Nicholson, L.; Delaglio, F.; Bax, A.; Torchia, D. Pulse sequences for removal of the effects of cross-correlation between dipolar and chemical-shift anisotropy relaxation mechanism on the measurement of heteronuclear T1 and T2 values in proteins. *J. Magn. Res.* **1992**, *97*, 359–375. [[CrossRef](#)]
40. Farrow, N.A.; Muhandiram, R.; Singer, A.U.; Pascal, S.M.; Kay, C.M.; Gish, G.; Shoelson, S.E.; Pawson, T.; Forman-Kay, J.D.; Kay, L.E. Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. *Biochemistry* **1994**, *33*, 5984–6003. [[CrossRef](#)]
41. Gryk, M.R.; Finucaine, M.D.; Zheng, Z.; Jardetzky, O. Solution dynamics of the trp repressor: A study of amide proton exchange by T1 relaxation. *J. Mol. Biol.* **1995**, *246*, 618–627. [[CrossRef](#)]
42. Musacchio, A. How SH3 domains recognize proline. *Adv. Protein Chem.* **2002**, *61*, 211–268.
43. Englander, S.W.; Kallenbach, N.R. Hydrogen exchange and structural dynamics of proteins and nucleic acids. *Q. Rev. Biophys.* **1983**, *16*, 521–655. [[CrossRef](#)] [[PubMed](#)]
44. Gryk, M.R.; Jardetzky, O. AV77 hinge mutation stabilizes the helix-turnhelix domain of trp repressor. *J. Mol. Biol.* **1996**, *255*, 204–214. [[CrossRef](#)] [[PubMed](#)]
45. Korzhnev, D.M.; Salvatella, X.; Vendruscolo, M.; Di Nardo, A.A.; Davidson, A.R.; Dobson, C.M.; Kay, L.E. Low-populated folding intermediates of Fyn SH3 characterized by relaxation dispersion NMR. *Nature* **2004**, *430*, 586–590. [[CrossRef](#)] [[PubMed](#)]
46. Dayhoff, M.O.; Schwartz, R.M.; Orcutt, B.C. A model of evolutionary change in proteins. In *Atlas of Protein Sequence and Structure*; Dayhoff, M.O., Ed.; National Biomedical Science Foundation: Washington, DC, USA, 1978; Volume 5, Suppl. 3, pp. 345–352.
47. Feng, S.; Chen, J.K.; Yu, H.; Simon, J.A.; Schreiber, S.L. Two binding orientations for peptides to the Src SH3 domain: Development of a general model for SH3–ligand interactions. *Science* **1994**, *266*, 1241–1247. [[CrossRef](#)] [[PubMed](#)]
48. Wu, X.; Knudsen, B.; Feller, S.M.; Zheng, J.; Sali, A.; Cowburn, D.; Hanafusa, H.; Kuriyan, J. Structural basis for the specific interaction of lysine-containing proline-rich peptides with the N-terminal SH3 domain of c-Crk. *Structure* **1995**, *3*, 215–226. [[CrossRef](#)]
49. Teyra, J.; Huang, H.; Jain, S.; Guan, X.; Dong, A.; Liu, Y.; Tempel, W.; Min, J.; Tong, Y.; Kim, P.M.; et al. Comprehensive analysis of the human SH3 domain reveals a wide variety of non-canonical specificities. *Structure* **2017**, *25*, 1598–1610. [[CrossRef](#)]
50. Li, S.S. Specificity and versatility of SH3 and other proline-recognition domains: Structural basis and implications for cellular signal transduction. *Biochem. J.* **2005**, *390*, 641–653. [[CrossRef](#)]
51. Yu, H.; Chen, J.K.; Feng, S.; Dalgarno, D.C.; Brauer, A.W.; Schreiber, S.L. Structural basis for the binding of proline-rich peptides to SH3 domains. *Cell* **1994**, *76*, 933–945. [[CrossRef](#)]
52. Lim, W.A.; Richards, F.M.; Fox, R.O. Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. *Nature* **1994**, *372*, 375–379. [[CrossRef](#)] [[PubMed](#)]
53. Moncalian, G.; Cardenas, N.; Deribe, Y.L.; Spinola-Amilibia, M.; Dikic, I.; Bravo, J. Atypical polyproline recognition by the CMS N-terminal Src homology 3 domain. *J. Biol. Chem.* **2006**, *281*, 38845–38853. [[CrossRef](#)] [[PubMed](#)]
54. Mongioli, A.M.; Romano, P.R.; Panni, S.; Mendoza, M.; Wong, W.T.; Musacchio, A.; Cesareni, G.; Di Fiore, P.P. A novel peptide-SH3 interaction. *EMBO J.* **1999**, *18*, 5300–5309. [[CrossRef](#)]
55. Kato, M.; Miyazawa, K.; Kitamura, N. A deubiquitinating enzyme UBPY interacts with the Src homology 3 domain of Hrs-binding protein via a novel binding motif PX(V/I)(D/N)RXXKP. *J. Biol. Chem.* **2000**, *275*, 37481–37487. [[CrossRef](#)] [[PubMed](#)]
56. Liu, Q.; Berry, D.; Nash, P.; Pawson, T.; McGlade, C.J.; Li, S.S. Structural basis for specific binding of the Gads SH3 domain to an RxxK motif-containing SLP-76 peptide: A novel mode of peptide recognition. *Mol. Cell.* **2003**, *11*, 471–481. [[CrossRef](#)]
57. Harkioliaki, M.; Lewitzky, M.; Gilbert, R.J.; Jones, E.Y.; Bourette, R.P.; Mouchiroud, G.; Sondermann, H.; Moarefi, I.; Feller, S.M. Structural basis for SH3 domain-mediated high-affinity binding between Mona/Gads and SLP-76. *EMBO J.* **2003**, *22*, 2571–2582. [[CrossRef](#)] [[PubMed](#)]
58. Kang, H.; Freund, C.; Duke-Cohan, J.S.; Musacchio, A.; Wagner, G.; Rudd, C.E. SH3 domain recognition of a proline-independent tyrosine-based RKxxYxxY motif in immune cell adaptor SKAP55. *EMBO J.* **2000**, *19*, 2889–2899. [[CrossRef](#)]
59. Duke-Cohan, J.S.; Kang, H.; Liu, H.; Rudd, C.E. Regulation and function of SKAP-55 non-canonical motif binding to the SH3c domain of adhesion and degranulation-promoting adaptor protein. *J. Biol. Chem.* **2006**, *281*, 13743–13750. [[CrossRef](#)]
60. Merő, B.; Radnai, L.; Gógl, G.; Tőke, O.; Leveles, I.; Koprivanacz, K.; Szeder, B.; Dülk, M.; Kudlik, G.; Vas, V.; et al. Structural insights into the regulation of SH3 domain function by phosphorylation of conserved tyrosine residues within the ligand binding groove. *J. Biol. Chem.* **2019**, *294*, 4608–4620. [[CrossRef](#)]
61. He, Y.; Hicke, L.; Radhakrishnan, I. Structural basis for ubiquitin recognition by SH3 domains. *J. Mol. Biol.* **2007**, *73*, 190–196. [[CrossRef](#)]
62. Chan, B.; Lanyi, A.; Song, H.K.; Griesbach, J.; Simarro-Grande, M.; Poy, F.; Howie, D.; Sumegi, J.; Terhorst, C.; Eck, M.J. SAP couples Fyn to SLAM immune receptors. *Nat. Cell. Biol.* **2003**, *5*, 155–160. [[CrossRef](#)]
63. Heuer, K.; Arbuzova, A.; Strauss, H.; Kofler, M.; Freund, C. The helically extended SH3 domain of the T cell adaptor protein ADAP is a novel lipid interaction domain. *J. Mol. Biol.* **2005**, *348*, 1025–1035. [[CrossRef](#)] [[PubMed](#)]

-
64. Heuer, K.; Sylvester, M.; Kliche, S.; Pusch, R.; Thiemke, K.; Schraven, B.; Freund, C. Lipid-binding hSH3 domains in immune cell adapter proteins. *J. Mol. Biol.* **2006**, *361*, 94–104. [[CrossRef](#)] [[PubMed](#)]
 65. Pérez, Y.; Maffei, M.; Igea, A.; Amata, I.; Gairí, M.; Nebreda, A.R.; Bernadó, P.; Pons, M. Lipid binding by the Unique and SH3 domains of c-Src suggests a new regulatory mechanism. *Sci. Rep.* **2013**, *3*, 1295. [[CrossRef](#)] [[PubMed](#)]